文献速递慢性静脉疾病静脉血栓栓塞

专用髂静脉支架在妊娠期和产后的结局

Outcomes of dedicated iliac venous stents during pregnancy and postpartum.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2023-04-06

本研究回顾性分析前瞻性收集的10例女性13次支架后妊娠数据,评估专用髂静脉支架在妊娠及产后的支架通畅性、完整性及血栓栓塞和出血并发症。所有支架在妊娠期、产后6周及末次随访均保持通畅,无深静脉血栓、肺栓塞或出血并发症,仅1例因支架内血栓再干预、1例无症状性支架受压。作者认为包含低剂量抗血小板联合预防或治疗剂量抗凝的方案似乎安全有效。

要点

  • 10例女性13次支架后妊娠中,专用髂静脉支架在妊娠期、产后6周及中位60个月随访均保持通畅。
  • 无深静脉血栓、肺栓塞或出血并发症,仅1例支架内血栓再干预、1例无症状性支架受压。
  • 作者认为低剂量抗血小板联合按风险分层的预防或治疗剂量抗凝方案似乎安全有效。

核心结论

  • 专用静脉支架在妊娠期和产后表现良好。
  • 包含低剂量抗血小板联合预防或治疗剂量抗凝(取决于患者风险特征)的方案似乎安全有效。

研究设计与样本

  • 本研究为回顾性分析前瞻性收集的数据,患者来自一家私立血管诊所。
  • 纳入育龄期接受专用髂静脉支架的女性,进入监测计划,后续妊娠遵循同一妊娠期护理方案。
  • 共分析10例女性13次支架后妊娠;7例因非血栓性髂静脉病变置入支架,3例因血栓后狭窄置入支架。
  • 所有支架均为专用静脉支架,其中4枚跨越腹股沟韧带。

主要发现

  • 所有支架在妊娠期、产后6周及末次随访(支架置入后中位时间60个月)均保持通畅。
  • 无深静脉血栓或肺栓塞病例,无出血并发症。
  • 仅1例因支架内血栓行再干预,1例无症状性支架受压。

关键数值与推荐

  • 抗血栓方案:每日100 mg阿司匹林至妊娠36周。
  • 低风险患者(因非血栓性髂静脉病变置入支架)从妊娠晚期开始接受预防剂量依诺肝素40 mg/天皮下注射。
  • 高风险患者(因血栓性指征置入支架)从妊娠早期开始接受治疗剂量依诺肝素1.5 mg/kg/天皮下注射。
  • 所有女性在妊娠期和产后6周接受双功超声评估支架通畅性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to assess the performance of dedicated iliac venous stents during subsequent pregnancy and postpartum, including stent patency and stent integrity, as well as incidence of venous thromboembolism and bleeding complications. METHODS: This study included retrospective analysis of prospectively collected data of patients attending a private vascular practice. Women of child-bearing age who had received dedicated iliac venous stents were included in a surveillance program and then, for any subsequent pregnancies, followed the same pregnancy care protocol. This included an antithrombotic regime of 100 mg aspirin daily until gestation week 36, and subcutaneous enoxaparin at a dose dependent on risk of thrombosis: low-risk patients, those stented for non-thrombotic iliac vein lesion, received a prophylactic dose of 40 mg/day from the third trimester; high-risk patients, those stented for thrombotic indication, received a therapeutic dose of 1.5 mg/kg/day from the first trimester. All women underwent follow-up with duplex ultrasound assessment of stent patency during pregnancy and at 6 weeks postpartum. RESULTS: Data was analyzed for a total of 10 women and 13 post-stent pregnancies. Stents were placed for non-thrombotic iliac vein lesions in seven patients, and for post-thrombotic stenoses in three patients. All stents were dedicated venous stents, and four crossed the inguinal ligament. All stents remained patent during pregnancy, at 6 weeks postpartum, and latest follow-up (median time post-stent, 60 months). There were no cases of deep vein thrombosis or pulmonary embolism, and no bleeding complications. There was only one reintervention case due to in-stent thrombus, and one case of asymptomatic stent compression. CONCLUSIONS: Dedicated venous stents performed well through pregnancy and post-partum. A protocol including the use of low dose antiplatelets in combination with anticoagulation at either a prophylactic or therapeutic dose depending on the patient's risk profile appears safe and effective.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Villalba L, Larkin TA. Outcomes of dedicated iliac venous stents during pregnancy and postpartum. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37030449. doi:10.1016/j.jvsv.2023.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。